The landscape of targeted therapies for cholangiocarcinoma: Current status and emerging targets

• المؤلفون الرئيسيون: Chong, D.Q, Zhu, A.X
• مؤلفون آخرون: DUKE-NUS MEDICAL SCHOOL
• التنسيق: Review
• منشور في: Impact Journals LLC 2020
• الموضوعات: B Raf kinase; bevacizumab; biological marker; bortezomib; cabozantinib; capecitabine; cediranib; ceritinib; cetuximab; cisplatin; dasatinib; epidermal growth factor receptor; erlotinib; fibroblast growth factor receptor 2; gemcitabine; hybrid protein; irinotecan; isocitrate dehydrogenase; K ras protein; lapatinib; oxaliplatin; panitumumab; ponatinib; protein p53; selumetinib; sorafenib; sunitinib; tivantinib; unindexed drug; vandetanib; FGFR2 protein, human; MET protein, human; programmed death 1 receptor; scatter factor receptor; vasculotropin receptor; advanced cancer; bile duct carcinoma; biliary tract cancer; cancer combination chemotherapy; cancer incidence; cancer patient; cancer prognosis; cancer survival; drug targeting; epithelium cell; exome; gene mutation; hepatobiliary system; human; liver cancer; liver cell carcinoma; metastasis; molecularly targeted therapy; next generation sequencing; nonhuman; Review; somatic mutation; antagonists and inhibitors; bile duct tumor; gene fusion; genetics; mutation; Bile Duct Neoplasms; Cholangiocarcinoma; Gene Fusion; Humans; Isocitrate Dehydrogenase; Molecular Targeted Therapy; Mutation; Programmed Cell Death 1 Receptor; Proto-Oncogene Proteins c-met; Receptor, Epidermal Growth Factor; Receptor, Fibroblast Growth Factor, Type 2; Receptors, Vascular Endothelial Growth Factor
• الوصول للمادة أونلاين: https://scholarbank.nus.edu.sg/handle/10635/180389
• المؤسسة: National University of Singapore

10.18632/oncotarget.8775